RecruitingNCT06458504
Viral Infection of HSPC Impacts Hematopoiesis
Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
45 participants
Start Date
Oct 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- HIV patients :
- HIV-positive patients with a negative or positive viral load.
- managed at Ambroise Paré Hospital.
- patients with a bone marrow biopsy or myelogram performed as part of their care.
- Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.
- Management at Ambroise Paré Hospital.
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06458504
Related Trials
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
NCT0651769317 locations
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
NCT062524022 locations
Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
NCT069677531 location